Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Telesis Bio Q3 Earnings

Telesis Bio (NASDAQ:TBIO) reported its Q3 earnings results on Monday, November 13, 2023 at 04:22 PM. Here’s what…
byBenzinga Insights
November 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Telesis Bio (NASDAQ:TBIO) reported its Q3 earnings results on Monday, November 13, 2023 at 04:22 PM.

Here’s what investors need to know about the announcement.

Earnings

Telesis Bio missed estimated earnings by 23.33%, reporting an EPS of $-0.37 versus an estimate of $-0.3.

Revenue was down $1.11 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.04 which was followed by a 5.76% drop in the share price the next day.

Here’s a look at Telesis Bio’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.32 -0.37 -0.41 -0.48
EPS Actual -0.28 -0.37 -0.28 -0.42
Revenue Estimate 8.60M 7.40M 7.20M 5.30M
Revenue Actual 8.65M 6.32M 9.47M 6.67M

To track all earnings releases for Telesis Bio visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Earnings Outlook For Fuel Tech

By Benzinga Insights
November 7, 2:16 PM
Fuel Tech (NASDAQ:FTEK) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Fuel Tech will report an earnings per share (EPS) of $-0.02.

FTEK

Read More

Dario Launches Agreement With Large Regional Health Plan And Announces Preliminary Results For Q2 2023 As Well As Business Update; Sees Q2 Revenue $6M-$6.15M Vs $6.73M Est.; Preliminary Unaudited Cash And Cash Equivalents Of $52.6M As Of June 30

By Happy Mohamed
July 24, 8:42 AM
New account is set to launch in July 2023 for eligible members NEW YORK, July 24, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in

DRIO

Read More

Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And ‘Substantial Growth’

By Jelena Martinovic
May 28, 8:42 AM
Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) announced on Tuesday its first quarter financial results for the three months ended March 31, 2024. The Toronto-based company reported a total revenue of CA$16.4 million ($12 million) (net revenue of CA$12.7 million, before excise duties and discounts), representing a 9% year-over-year increase. "Entourage's first quarter results are a testament to our robust financial health and strategic approach to business operations, positioning us for success throughout 2024," George Scorsis, the company's chair and CEO, said. "With defined infrastructure and supply agreements in place, we are well-positioned to continue delivering the accelerated growth we have already seen develop in Q1."

ETRGF